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This study aimed at designing mucoadhesive microemulsion gel to enhance the brain uptake of Ibuprofen 
through intranasal route. Ibuprofen loaded mucoadhesive microemulsion (MMEI) was developed by 
incorporating polycarbophil as mucoadhesive polymer into Capmul MCM based optimal microemulsion 
(MEI) and was subjected to characterization, stability, mucoadhesion and naso-ciliotoxicity study. Brain 
uptake of ibuprofen via nasal route was studied by performing biodistribution study in Swiss albino 
rats. MEI was found to be transparent, stable and non ciliotoxic with 66.29 ± 4.15 nm, -20.9 ± 3.98 mV 
and 98.66 ± 1.01% as average globule size, zeta potential and drug content respectively. Transmission 
Electron Microscopy (TEM) study revealed the narrow globule size distribution of MEI. Following 
single intranasal administration of MMEI and MEI at a dose of 2.86 mg/kg, uptake of ibuprofen in the 
olfactory bulb was around 3.0 and 1.7 folds compared with intravenous injection of ibuprofen solution 
(IDS). The ratios of AUC in brain tissues to that in plasma obtained after nasal administration of MMEI 
were significantly higher than those after intravenous administration of IDS. Findings of the present 
investigation revealed that the developed mucoadhesive microemulsion gel could be a promising approach 
for brain targeting of ibuprofen through intranasal route.
Uniterms: Ibuprofen/brain-targeting. Ibuprofen/intranasal administration. Ibuprofen/mucoadhesion. 
Mucoadhesive microemulsion gel. Drugs/design. Transmission electron microscopy.
O objetivo deste trabalho foi planejar microemulsão/mucoaesiva em gel a fim de melhorar a captação 
cerebral de ibuprofeno por via intranasal. A microemulsão para mucoadesão com ibuprofeno (MMEI) foi 
desenvolvida pela incorporação de policarbofil como polímero mucoadesivo em microemulsão otimizada 
(MEI) com base em Capmul (MCM) e foi submetida à caracterização, estabilidade, mucoadesão e 
naso-ciliotoxicidade. A captação cerebral de ibuprofeno pela via nasal foi estudada por meio de estudo 
de biodistribuição em ratos albinos suíços. MEI se mostrou transparente, estável e não ciliotóxica, 
com 66,29 ± 4,15 nm, -20,9 ± 3,98 mV e 98,66 ± 1,01%, respectivamente, de tamanho médio dos 
glóbulos, potencial zeta e conteúdo do fármaco. O estudo revelou o estreita distribuição do tamanho 
dos glóbulos de MEI. Após administração intranasal única de MMEI e MEI, em dose de 2,86 mg/kg, 
a captação de ibuprofeno no bulbo olfativo foi em torno de 3,0 e 1,7 vezes maior, comparativamente, 
à injeção endovenosa de ibuprofeno (IDS). As taxas de ASC em tecido cerebral em relação ao plasma, 
obtidas após administração da MMEI nasal, foram, significativamente, mais elevadas do que aquelas 
observadas após a administração intravenosa de IDS. Os resultados do presente estudo mostraram que 
a microemulsão/mucoadesiva em gel poderia ser uma abordagem promissora para o direcionamento 
cerebral de ibuprofeno por via intranasal.
Unitermos: Ibuprofeno/captação cerebral. Ibuprofeno/administração intranasal. Ibuprofeno/mucoadesão. 
Microemulsão mucoadesiva/em gel. Fármacos/desenvolvimento. Microscopia de transmissão eletrônica.
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INTRODUCTION
Recently, nonsteroidal anti-inflammatory drugs 
(NSAIDs) appear to be protective in animal models of 
Parkinson’s disease (PD) and regular use of NSAIDs 
may reduce the risk of PD in humans (Lang, Lozano, 
1998, Tansey, Goldberg, 2010). Some other findings 
showed that NSAIDs may delay or prevent the onset of 
PD. Ibuprofen (2-(4-(2-methylpropyl) phenyl)propanoic 
acid), a NSAID used for relief of symptoms of arthritis 
and fever. However, the clinical usefulness of ibuprofen 
is limited by its high first-pass metabolism in liver, which 
leads to low oral bioavailability and poor brain entry due 
to over expression of p-glycoprotein (Chen et al., 2008). 
Therefore, looking for alternative routes of administration 
to improve therapeutic effects is necessary. 
In recent years, drug delivery through nasal route 
has received a lot of attention, because it offers several 
advantages including rapid absorption of drug, avoidance 
of hepatic first-pass metabolism, and drug delivery 
preferentially to brain via the olfactory region (Woensel 
et al., 2013). Therefore, the nasal route to the brain may 
provide a better alternative to oral administration of 
Ibuprofen. For nasal delivery of Ibuprofen, a challenge 
existing in formulation development is the solubilization 
of poorly water-soluble Ibuprofen. Secondly effective 
nasal delivery volume in human is ≤400μl (200μl per 
nostril), hence normal solution did not provide satisfactory 
solubility for nasal delivery of Ibuprofen.
M i c r o e m u l s i o n s  ( M E s )  a r e  i s o t r o p i c , 
thermodynamically stable transparent systems of oil, 
water and surfactant, frequently in combination with a 
cosurfactant with a droplet size usually in the range of 20-
200 nm (Shah et al., 2014). These systems are currently of 
great scientific interest to the researchers because of their 
potential to incorporate a wide range of drug molecules 
(hydrophilic and hydrophobic) due to the presence of 
both lipophilic and hydrophilic domains (Pathak et al., 
2014). Moreover, these versatile delivery systems provide 
protection against oxidation, enzymatic hydrolysis and 
improve the solubilization of lipophilic drugs and hence 
enhance their bioavailability (Talegaonkar et al., 2008). 
In addition, they are amenable for sustained and targeted 
delivery through oral, ophthalmic, pulmonary, vaginal, 
intravenous and topical routes (Ghosh, Murthy, 2006, 
Abdelrahim, Abdelbary, Ghorab, 2011). MEs, by virtue 
of their lipophilic nature and low globule size, are widely 
explored as a delivery system to enhance CNS uptake across 
nasal mucosa. Addition of mucoadhesive agent such as a 
polyelectrolyte polymer helps in retention of formulation 
in nasal cavity that further facilitates the absorption. The 
retention is due to the electronic interaction between mucin 
of nasal mucosa and the polymer (Rhee et al., 2007). 
Evidences of intranasal drug delivery systems formulated 
using mucoadhesive agent and its benefits in enhancing 
nose-to-brain drug transport have been reported by various 
scientists in the literature (Porecha et al., 2009).
Hence the objective of this investigation was 
to prepare, characterize and to perform comparative 
biodistribution study of the developed formulations in rat, 
and to also assess direct nose-to-brain transport. It was 
hypothesized that MEI / MMEI will result in effective 
nose-to-brain transport, enhanced rate and extent of drug 
transport, and greater distribution of Ibuprofen within and 
into the brain. This can help to maximize the therapeutic 
index of the drug, reduce its side effects, reduce the dose 
and frequency of dosing, and perhaps result into cost 
effectiveness (Ponchel et al., 1997; Botner, Sintov, 2011). 
MATERIAL AND METHODS
Material
Ibuprofen was obtained as gift sample from Abbott 
India Ltd., Goa, India. Aceclofenac was procured from 
Alembic ltd., Baroda, India. Capmul MCM, Captex, 
Labrafac CC, Cremophor EL, Accenon CC and Transcutol 
P were received as gifts from ABITEC, Mumbai, India. 
Polycarbophil (AA-1, pharmagrade, molecular weight 
approximately 3.5 million) was procured as gift sample 
from Lubrizol Advanced Material India Pvt Ltd. (Mumbai, 
India). Isopropyl myristate (IPM), Oleic Acid (OA), 
polyethylene glycol 400 (PEG 400), PEG 600, Tween 60, 
Tween 80, glycerol, isopropyl alcohol, isobutyl alcohol, 
sodium deoxycholate, citric acid (monohydrate), disodium 
phosphate (dihydrate) and propranolol were purchased 
from Baroda Chemicals, Vadodara, India. HPLC grade 
sodium dihydrogen phosphate (NaH2PO4), disodium 
hydrogen phosphate Na2HPO4), n-hexane, diethyl ether, 
p-phenylphenol and acetonitrile procured from Merck, 
India. Double distilled water was prepared by using 
Millipore Milli Q plus purification system.
METHODS
Analytical methodology
Ibuprofen in solubility study samples as well as 
in brain and blood samples was analyzed by developed 
reversed phase high performance liquid chromatography 
(RP-HPLC) method (Albert et al., 2006; Choudhary, 
Aroba, Sharma, 2012). HPLC analysis was performed 
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using Waters 515 Series pumps combined with a Waters 
PDA 2998 series photo diode array detector (DAD). The 
column used was Agilent C18 column (150 mm×4.6 
mm, particle size 5-micron Agilent, USA). Analysis was 
isocratic at 0.8 ml/min flow rate with ACN: Buffer (0.025 
M potassium dihydrogen ortho phosphate) pH 4.5 at 11:9 
v/v as mobile phase. The mobile phase was developed by 
mixing and filtered through a 0.2 µm nylon membrane 
filter followed by degassing by sonication before use. The 
elution of drug was detected at 230nm.
Selection of formulation components
Selection of the oil was mainly based on the solubility 
of the drug. Different oils like isopropyl myristate, Capmul 
MCM, Labrafac CC, Oleic acid, Labrafil M 1944CS and 
Soyabean oil were screened for solubility study. Selection 
criteria for surfactant were its HLB value, drug solubility 
and non-toxic nature. Several surfactants like Tween-60, 
Tween-80, Captex-355, Accenon CC, and Cremophor 
EL having HLB value ranging in between 12 to 18, were 
screened. Screening of co-surfactants was based on 
their ability to form stable and clear microemulsion at a 
minimum concentration and several co-surfactants like 
PEG 400, PEG 600, propylene glycol, glycerol, isobutyl 
alcohol, isopropyl alcohol and Transcutol P were screened. 
Excess of Ibuprofen was added to each cap vial containing 
5 ml of each of the selected vehicle. After sealing, mixtures 
were shaken with shaker at 37 oC for 48 h. After reaching 
equilibrium, each vial was centrifuged at 8000 rpm for 
10 min and excess insoluble Ibuprofen was separated by 
filtration using Whatman filter (0.45μ). Both free drug 
as well as solubilized drug concentration was quantified 
by UV-VIS Spectrophotometer (Shimadzu UV1800) and 
mass balance was done (Vogt, Kunath, Dressman et al., 
2008; Patel et al., 2010). 
Pseudoternary phase diagram study
The pseudoternary phase diagrams of oil, surfactant: 
co-surfactant (Smix), and water were developed using 
distilled water titration method. The mixture of oil and at 
different ratio of Smix (1:0.5, 1:1, 1.5:1, 2:1, 2.5:1 and 3:1) 
at certain volume ratio were titrated with distilled water in 
drop wise manner. Using Chemix software, microemulsion 
regions were determined and Smix showing maximum 
microemulsion region was used for the development of 
microemulsion (Moghimipour, Anayatollah, Fatemeh, 
2012; Subudhi, Mandal, 2013). 
Preparation of formulations
Ibuprofen loaded microemulsion (MEI) was 
prepared by water titration method. Predetermined amount 
of Ibuprofen was dissolved in the required quantity of 
selected oil. Surfactant and cosurfactant concentration 
(Smix) from the result of pseudo-ternary phase diagrams 
was added to the above drug oil mixture. Finally this 
mixture of oil and Smix was titrated dropwise by 
distilled water with mild but continuous stirring until a 
transparent and homogenous microemulsion was produced 
(Patel, Mandal, Rajesh, 2012; Khan et al., 2009). Then 
microemulsion was formulated into microemulsion based 
gel (MMEI) using polycarbophil as mucoadhesive agent 
(Sharma et al., 2009). Ibuprofen solution (IDS, 20 mg/mL) 
was prepared by addition of Ibuprofen (200 mg) to 8 ml of 
distilled water and ethanol (8:2) with continuous stirring. 
The pH was adjusted to 6.8 ± 0.25 using glacial acetic acid 
(approximately 0.06 ml/ml). The mixture was stirred for 
10 min and a clear solution was obtained. Final volume 
was made up to 10 ml using distilled water (Piao et al., 
2010). pH of the final formulation was also checked.
Characterization
Characterization of microemulsion formulations
All measurements were performed in triplicates. 
Optimized MEI was characterized for % Transmittance, 
globule size, zeta potential, pH and drug content. % 
Transmittance and drug content were measured by 
UV-VIS Spectrophotometer (Shimadzu UV1800) at 
650 nm (Mandal et al., 2010) and 222 nm (Joshi et al., 
2011) respectively. Globule size and zeta potential were 
determined by Zetasizer (Nano ZS, Malvern Instruments, 
UK) at a temperature of 25 ± 2 oC.
For determination of drug content, about 0.5 g of 
MMEI was weighed in a 100 ml volumetric flask and 
dissolved in 50 mL of phosphate buffer of pH 7.4. The 
volumetric flask was kept for 2 h and shaken well in a 
shaker to mix it properly. It was diluted appropriately and 
analyzed on a UV-VIS Spectrophotometer (Shimadzu UV 
1800) at 222 nm.
For spreadability of the gel, 0.5 g of MMEI was 
placed on a glass plate within a premarked circle of 1 cm 
diameter. Over which a second glass plate was placed and a 
weight of 500 g was allowed to rest on the upper glass plate 
(Joshi, Patravale, 2006). Spreading of the gel with respect 
to the increase in the diameter after 1 min was noted. 
MEI and MMEI pH were determined by digital pH 
meter (Systronics, India). For pH of the gel, 1.0 g of gel 
was dissolved in 100 mL of distilled water, stored for 2 h 
and then the pH was measured in triplicate by calibrated 
digital pH meter (Dhawan, Medhi, Chopra, 2009). 
The viscosity of the developed MMEI was 
determined in triplicate at 25 ± 1.0 oC by Brookefield 
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Viscometer (Model RVT). The sample (30 g) was placed 
in a beaker and was allowed to equilibrate for 5 min before 
measuring the dial reading using T-C spindle (spindle no 
64 ) at 10 rpm (Joshi, Patravale, 2006; Fanun, 2010). 
A drop of diluted MMEI was placed onto the surface 
of a copper grid coated with carbon. Upon drying, the 
grids with mesh size of 300 were stained with 2%(w/v) 
phosphotungstic acid for 120 s and dried at room 
temperature and probed with Transmission Electron 
Microscopy (TEM). The process was performed at room 
temperature. Images were captured at the magnification of 
×48,000 to ×1,50,000 (Chudasama et al., 2011).
Nasal ciliotoxicity
Nasal ciliotoxicity studies were carried out using 
excised sheep nasal mucosa. In brief, the excise nasal 
mucosa of sheep was exposed and treated with 1 g of test 
MMEI containing Ibuprofen at 2.86 mg/mL for 1 h, then 
rinsed with saline. The mucocilia was then examined with 
an optical microscope (Nikon Fx-35A, Japan). Saline and 
propranolol (a serious nasal mucociliary toxicity agent, 
1%(w/v) solution) were used as a negative and positive 
control, respectively (Mandal, Mandal 2010, Mandal et 
al., 2010). 
Stability study
Stability of the developed MMEI was carried 
according to ICH guideline for 6 months (Bachhav, 
Patravale, 2009). Optimized microemulsion was kept 
at cold temp (4-8 °C), room temperature and at elevated 
temperature (50 ± 2 °C). After every 2 month for 6 
months, MMEI was analyzed for phase separation, % 
transmittance, globule size and % assay.
Animal experiment
All animal experiments were approved by 
Committee for the Purpose of Control and Supervision 
of Experiments on Animals (CPCSEA), Ministry of 
Social Justice and Empowerment, Government of India, 
New Delhi, India. Male Albino rats (250 ± 20 g) were 
used for the comparative in-vivo permeation study. The 
animals were maintained at temperature (25 ± 2 °C), and 
humidity (60 ± 5 %) and were supplied with food and 
water ad libitum. Male Albino rats weighing 250 ± 20 g 
were anesthetized with an intraperitoneal pentobarbital 
injection (40 mg/kg) and kept on a heating pad to maintain 
the body temperature (Mandal, 2011). 35-40 μL of 
the developed nasal formulation containing Ibuprofen 
equivalent to 2.86 mg/kg were administered intranasally 
with the help of a micropipette (200 μL) attached to low 
density polyethylene tubing with internal diameter 0.1 
mm at the delivery site. For i.v. administration, 0.5 mL 
of IDS was delivered (dose equivalent to 2.86 mg/kg) 
through the femoral vein (Elshafeey, Bendas, Mohamed, 
2009). At 2, 5, 10, 15, 30, 60, 120, 240 and 360 min after 
the dose, blood was collected by cardiac puncture (Hoff, 
2000; Hamza et al., 2014). Then the skull was cut open and 
the olfactory bulb (OB), olfactory tract (OT), cerebrum 
(CER) and cerebellum (CEB) were carefully excised. Each 
brain tissue was quickly rinsed with saline and bottled up 
with filter paper to get rid of blood-taint and macroscopic 
blood vessels as much as possible. After weighing, the 
brain tissue samples were homogenized with 5 ml of saline 
in a tissue homogenizer (BD-144 Tissue Homogenizer, 
India). Blood samples were anticoagulated with heparin 
and centrifuged at 6000 rpm for 10 min to obtain plasma. 
All samples, i.e. aliquots of plasma, and brain tissues 
homogenates, were stored for up to 48 h in a deep freezer 
(-20 oC) until HPLC analysis. Measurements were made 
using 3 rats at each time point. 
Analytical procedures
Ibuprofen in plasma and brain tissue was assayed 
according to a modified HPLC method (Thomas, Savage, 
1985; Choudhary, Arora, Sharma, 2012). Ibuprofen is 
extracted from plasma treated with 1.0 M phosphoric acid 
for acidification using hexane and using p-phenylphenol 
as an internal standard. To 200 μL plasma samples 
internal standard was added and was vortexing for 2 mins. 
Chromatographic separation achieved isocratically on a 
C18 column (Inertsil, 150 mm x 4.6 mm) utilizing a mobile 
phase of acetonitrile/phosphate buffer/water (60:30:10, 
v/v, pH 7.0) at a flow rate of 1.2 ml/min with UV detection 
at 230 nm. 80-400 μL brain tissue homogenates, 30 μg/
mL of aceclofenac as internal standard was added and was 
vortexing for 2 min. After centrifugation at 10,000 rpm 
for 10 min, the drug was extracted from the supernatant 
by adding 0.7 mL of n-hexane and diethylether (1:1). The 
separated organic phases were then evaporated to dryness 
at 40 0C. The residue was reconstituted in 100 μL mobile 
phase and then 20 μL was injected onto an HPLC system 
consisting of a LC-20AT VP solvent delivery system and 
SPD-20A UV detector (Shimadzu, Japan). In order to 
analyze brain tissue samples, same mobile phase i.e., 60% 
acetonitrile, 30% phosphate buffer and 10% water (v/v, pH 
7.0) at a flow rate of 1.2 mL/min was used and analyzed 
at 230 nm. The retention time was 12.8 min for Ibuprofen 
and 9.2 min for the internal standard i.e., Aceclofenac. 
The linear range of Ibuprofen was 20-600 ng/ml and 
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20-1000 ng/g for plasma, and brain tissue respectively. 
Extraction recoveries of ibuprofen from plasma and tissue 
homogenates were more than 86% and 77% respectively.
Statistical analysis
All data are reported as mean ± SD and the difference 
between the groups were tested using Student’s t-test at the 
level of P < 0.05. More than two groups were compared 
using ANOVA and differences greater at P < 0.05 were 
considered significant.
RESULTS AND DISCUSSION
Preparation and characterization of MMEI
Since Capmul MCM is a biocompatible vehicle and 
has got maximum drug solubilizing capacity compared 
to the screened oils i.e., 62.54 ± 1.23 mg/mL, hence it 
was selected as oil phase. Accenon CC has got less drug 
solubilizing capacity with HLB value equals to 15.6 
was selected as surfactant with the intension to provide 
sustained release. Results of pseudo-ternary phase 
diagrams were also depicted that Accenon CC as surfactant 
and Transcutol P as cosurfactant with Smix (3:1) were 
suitable for the development of microemulsion. 
% Transmittance of MEI was found to 99.7 ± 0.12 
% indicating the transparency of the system. The average 
globule size was 66.29 ± 4.15 nm with PdI equals to 
0.183 ± 0.19. Moreover results of % Transmittance and 
average globule size as shown in Figure 1, indicates the 
nano size range of the formulation. PdI value indicated 
about monodisperse property of the formulation (Rao, 
Mcclements, 2011).
Average zeta potential of IME was found to be 
-20.9 ± 3.98 mV as shown in Figure 2 indicates the 
stability of the formulation. This may be because moderate 
negative surface charges resulted neither into strong 
aggregation nor repulsion of the globules (Mandal, 2011). 
Ibuprofen content was found to be 99.38 ± 0.17 
%, 99.22 ± 0.23 % and 98.99 ± 0.27 % for MEI, MMEI 
and IDS respectively. pH of the developed formulations 
were around 6.4-6.8 indicating the suitability for nasal 
administration. No significant deviations were observed 
as shown in Table 1, in terms of phase separation, % 
transmittance, globule size and % assay indicating that 
developed formulations were physical stable for 6 months 
at all three storage conditions and hence the formulation 
may be stored at room temperature. The altered storage 
conditions were found to have no adverse effect on the 
stability of the optimal formulation. TEM result as shown 
in Figure 3 revealed the narrow particle size distribution.
Optical microscopic results showed that there was 
no epithelial damage of cilia on the edge of mucosa that 
was treated with developed microemulsion formulations 
for 1 h. This result as shown in Figure 4 [A] revealed that 
the developed MMEI was non-ciliotoxic and was suitable 
FIGURE 1 - Average globule size with PdI indicating the monodispersity of ibuprofen loaded microemulsion.
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for nasal application and as in Figure 4 [C] treated with 
saline. Formulation treated with 1% v/v propranolol 
showed severe alteration of mucosal layer as shown in 
Figure 4 [B].
The spreading diameter in mm of the prepared 
MMEI was found to be 56 ± 5 mm after 1 min. This 
spreadability result indicated that the prepared MMEI 
was easily spreadable by small amount of shear and hence 
showed excellent spreadability (Misal, Dixit, Gulkari, 
2012). The drug content of the MMEI was found to be 
97.44 ± 0.71% and pH was found to be 6.29 ± 0.18, 
which are within the acceptable limits and suitable for 
FIGURE 2 - Average zeta potential result of the optimized MEI indicating the stability of the formulation.
FIGURE 3 - TEM result of the optimized MEI indicating the 
narrow particle size distribution.
FIGURE 4 - Result of nasocilio toxicity study (A) Indicating the nontoxic property of developed MMEI on the nasal cilia. (B) Result 
of nasocilio toxicity study treated with propranolol showing destruction of cilia. (C) Result of nasocilio toxicity study treated with 
saline as negative control which shows no ciliary destruction.
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intranasal application. Viscosity of the gel was found to 
be 32,540 ± 7.63 cPs indicating the easy applicability of 
the formulation into the nasal cavity.
Brain uptake study
Plasma and brain tissue concentration-time profiles 
of ibuprofen after nasal administration of MMEI at 2.86 
mg/kg dose in rats and intravenous administration of IDS 
was estimated. The non-compartmental pharmacokinetic 
parameters were given in Table II.
Sustained absorption of Ibuprofen from MMEI 
into systemic circulation following intranasal delivery 
was observed and the maximum plasma concentration 
was achieved at 1 h. The plasma levels remained constant 
for 3 h. Following intravenous administration of IDS, 
brain Ibuprofen concentrations reached peak level at 10 
min and declined fast with time. Following intranasal 
administration of developed MMEI, Ibuprofen level in 
brain displayed that maximum concentration achieved 
after about 30 min in OB and 60-120 min in other 
regions of the brain. Ibuprofen content was also differed 
considerably in different brain regions. The highest 
concentration was observed in the OB (the peak drug level 
was 1090.2 ± 332.4 ng/g), followed by the olfactory tract, 
then the cerebellum and cerebrum. These findings support 
the existence of a nose–brain direct pathway following the 
intranasal administration. As shown in Figure 5, Ibuprofen 
was particularly concentrated in the OB after nasally 
administered MMEI, the AUC0→360 value was 2.98 times 
(74569 ± 3617 ng.min/g versus 24992 ± 1622 ng.min/g) 
that obtained after i.v. injection of IDS.
However, the uptakes of Ibuprofen into other brain 
regions after nasal dosing of MMEI were lower than 
those after i.v. injection as shown in Table II. This may be 
due to the following reason, in contrast to cerebrum and 
cerebellum, the mass of the OB is small. The distribution 
of Ibuprofen from OB through olfactory pathway into 
other brain regions could be counteracted by their large 
masses, thus leading to the insignificant increase in 
Ibuprofen content in other brain tissues (Bechgaard, 
Gizurarson, Hjortkjaer, 1997). In order to evaluate the 
brain targeting through nasal delivery of MMEI, the 
brain-to-plasma Ibuprofen AUC ratios at 10, 60, 360 
min following both i.v. and i.n. routes were calculated. 
Results showed that the ratio of AUC in brain tissues to 
TABLE I - Results of stability study 
Storage condition Months
Parameters
% Transmittance Particle size (nm) % Assay
2 °C-8 °C (35±5% RH)
2 98.4 ± 1.1 67.8 ± 2.1 98.7 ± 1.2 
4 97.1 ± 1.3 69.4 ± 1.9 97.9 ± 0.9 
6 97.4 ± 1.8 73.1 ± 1.7 97.4 ± 1.1
RT (45±5% RH)
2 99.8 ± 1.3 62.7 ± 1.8 99.2 ± 1.5
4 98.9 ± 1.7 72.2 ± 2.3 98.1 ± 0.9
6 97.6 ± 1.9 65.8 ± 1.5 99.5 ± 1.2
48 °C-52 °C (85±5% RH)
2 98.2 ± 1.6 63.3 ± 1.8 98.8 ± 0.7
4 98.7 ± 1.5 66.6 ± 1.4  97.9 ± 0.9
6 97.1 ± 0.9 73.7 ± 1.6 98.1 ± 0.7
(Result = mean ± SD, n =3).
TABLE II - Pharmacokinetic parameters after intravenous and intranasal administration of IDS and MMEI respectively (n=3)
Parameters and routes Plasma OB OT CER CEL
Cmax (ng/mL.g) (intranasal) 73.4±14.4 1090.2 ±452.4 315.2 ±101.6 157.8 ±19.3 7164.4 ±9.8
Cmax (ng/mL.g) (intravenous) 807.6±86.9 2976.2±255.5 3211 ±199.3 3164 ±246.9 3016 ±184.8
AUC0→360 (ng.min/mL.g) Intranasal 23185±1330 74569±3617 9228±1201 6829±4217 5164±958
AUC0→360 (ng.min/mL.g) Intravenous 61655±2348 24992±1622 13612±1016 17292±627 10405±1988
% [AUCi.n. /AUCi.v.] 37.61 298.37 67.79 39.49 49.63 
OB- Olfactory bulb; OT- Olfactory tract; CER-Cerebrum; CEL- Cerebellum. (Result= mean± SD, n =3)
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that in plasma after nasal administration of MMEI were 
significantly higher (P<0.05) than those after i.v. injection 
of IDS. For example, at 10 min after nasal dosing, the 
AUC ratio was 6.8 times higher than that after i.v. dosing 
(19.8 ± 2.2 versus 3.2 ± 0.4) in OB (Figure 6 A). Similarly 
17.2 times (48.8 ± 9.2 versus 5.31 ± 0.81) and 9.4 times 
(10.66 ± 1.01 versus 1.14 ± 0.36) increment of Ibuprofen 
concentration in OB following intranasal and intravenous 
delivery at the time points 30 and 360 min as shown in 
Figure 6 B and Figure 6 C respectively. 
Following intranasal administration, about 19-86% 
of Ibuprofen content at 6 h was transported to the brain 
via the olfactory pathway (Botner, Sintov, 2011). In 
short, these results support the existence of an alternative 
brain entry pathway for Ibuprofen by formulating in o/w 
mucoadhesive microemulsion because of its protection 
against enzymatic hydrolysis which may be due to the 
rapid drug absorption (Yang, Gao, Mitra, 2001; Bitter, 
Katja, Surber, 2011; Haque et al., 2012) and increasing 
the quantity of drug to the brain.
CONCLUSION
Results demonstrated that polycarbophil based 
mucoadhesive microemulsion system comprising Capmul 
MCM (3% v/v), Accenon CC (26% v/v), Transcutol P 
(9% v/v) and distilled water (62% v/v) was optimal for 
intranasal delivery of Ibuprofen. The microemulsion 
systems are transparent and physical stable at ambient 
conditions for 6 months. Results of Bioditribution study 
confirmed that a fraction of Ibuprofen could be transported 
directly into the brain after nasal delivery. Enhanced rate 
and extent of transport of Ibuprofen following intranasal 
administration of MMEI may help in decreasing the 
dose and frequency of dosing and possibly maximize the 
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and blood after intranasal delivery.
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FIGURE 6 - AUC of Ibuprofen in plasma and different parts of 
brain after intranasal and intravenous delivery of IMME and 
IDS respectively (n=3).
Mucoadhesive microemulsion of ibuprofen: design and evaluation for brain targeting efficiency through intranasal route 729
therapeutic index. However, ratio of clinical benefits to the 
risk of the formulation developed in this investigation will 
decide its appropriateness in the clinical practice.
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